Please login to read the full text of the article.
If you have no account yet, please register now.
Posted on
Previous Article
« The Italian experience: DOAC more cost-effective than VKA Next Article
Rivaroxaban monotherapy non-inferior to combination therapy in AF and stable CAD patients »
« The Italian experience: DOAC more cost-effective than VKA Next Article
Rivaroxaban monotherapy non-inferior to combination therapy in AF and stable CAD patients »
Related Articles
February 26, 2020
Icosapent ethyl plus statins reduces total plaque volume
November 13, 2020
Amgen drug shaves 8% off risk of heart-failure event or heart death
February 26, 2020
Full GALILEO results: Why did rivaroxaban fail after TAVR?
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy